Molecular markers in oral epithelial dysplasia: Review

Journal of Oral Pathology and Medicine

Volumn 38, Issue 10, 2009, Pages 737-752

  Pitiyage, Gayani ^a   Tilakaratne, W M ^a   Tavassoli, Mahvash ^b   Warnakulasuriya, Saman ^b  

^a UNIVERSITY OF PERADENIYA   (Sri Lanka)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cell cycle; Epithelial dysplasia; Loss of heterozygosity; Oncogenes; Oncosuppressor genes; Ploidy

Indexed keywords

CELL ADHESION MOLECULE; CYCLIN DEPENDENT KINASE; CYCLINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MOLECULAR MARKER; MYC PROTEIN; PROTEIN MDM2; PROTEIN P14; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53; PROTEIN P63; PROTEIN P73; RAS PROTEIN; TELOMERASE; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOSKELETON; DIAGNOSTIC ACCURACY; DYSPLASIA; EPSTEIN BARR VIRUS; GENETIC MARKER; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN HERPESVIRUS 8; MALIGNANT TRANSFORMATION; METAPLASIA; MOUTH CARCINOMA; MOUTH MUCOSA; MUTATION; ONCOGENE MYC; ONCOGENE RAS; PLOIDY; PRECANCER; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIUM; GENES, TUMOR SUPPRESSOR; HUMANS; METAPLASIA; MOUTH MUCOSA; MOUTH NEOPLASMS; ONCOGENES; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 70350437749     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00804.x     Document Type: Review

References (216)

1. Warnakulasuriya S, Johnson NW, Van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007 36 : 575 580.
2. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008 37 : 1 10.
3. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weakness and scope for improvement. J Oral Pathol Med 2008 37 : 127 133.
4. Reibel J. Prognosis of oral premalignant lesions: significance of clinical, histopathlogical, and molecular biological characteristics. Crit Rev Oral Biol Med 2003 14 : 47 62.
5. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol 1995 79 : 321 329.
6. Silverman S, Gorosky M, Lozada F. Oral leukoplakia and malignant transformation: a follow up study of 257 patients. Cancer 1984 53 : 563 568.
7. Schepman K, Van der Meij EH, Smeele LE, Van der Waal I. Concomitant leukoplakia in patients with oral squamous cell carcinoma. Oral Dis 1999 5 : 206 209.
8. Gupta PC, Mehta FS, Daftary DK, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980 8 : 287 333.
9. Pindborg JJ, Reibel J, Roed-Peterson B, Mehta FS. Tobacco induced changes in oral leukoplakic epithelium. Cancer 1980 45 : 1330 1336.
10. Cowan CG, Gregg TA, Napier SS, McKenna SM, Kee F. Potentially malignant oral lesions in Northern Ireland: a 20-year population-based perspective of malignant transformation. Oral Dis 2001 7 : 18 24.
11. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 1975 36 : 1021 1028.
12. Barnes L, Eveson JW, Reichart P, Sidransky D. World Health Organization classification of tumours of head and neck. Lyon : IARC, 2005 177 180.
13. Warnakulasuriya KAAS. Histological grading of oral epithelial dysplasia: revisited. J Pathol 2001 194 : 294 297.
14. Smith C, Pindborg JJ. Histological grading of oral epithelial atypia by the use of photographic standards. C. Hambergers Bogtrykkeri : Copenhagen, 1969.
15. Katz HC, Shear M, Altini M. A critical evaluation of epithelial dysplasia in oral mucosal lesions using the Smith-Pindborg method of standardization. J Oral Pathol 1985 14 : 476 482.
16. Speight P, Farthing PM, Bouquot JE. The pathology of oral cancer and pre cancer. Curr Diagn Pathol 1996 3 : 165 177.
17. Tabor MP, Braakhuis BJM, van der Waal JE, et al. Comparative molecular and histological grading of epithelial dysplasia of the oral cavity and the oropharynx. J Pathol 2003 199 : 354 360.
18. Schepman K, Van der Meij EH, Smeele LE, Van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital based population of 166 patients with oral leukoplakia from the Netherlands. Oral Oncol 1998 34 : 270 275.
19. Bosman FT. Dysplasia classification: pathology in disgrace? Pathology 2001 194 : 143 144.
20. Abbey LM, Kaugars GE, Gunsolley JC, Burns JC, Page DG, Svirsky JA. Intra-examiner and inter-examiner reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 80 : 188 191.
21. Karabulut A, Reibel J, Therkildsen MH, Praetorius F, Nielsen HW, Dabelsteen E. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 1995 24 : 198 200.
22. Pindborg JJ, Reibel J, Holmstrup P. Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol 1985 14 : 698 708.
23. Kujan O, Khattab A, Oliver R, Roberts SA, Thakker N, Sloan P. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol 2007 43 : 224 231.
24. Pindborg JJ, Daftary DK, Mehta FS. A follow-up study of sixty one oral dysplastic precancerous lesions in Indian villagers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1977 43 : 383 390.
25. Kramer IR, el-Labban N, Lee KW. The clinical features and risk of malignant transformation in sublingual keratosis. Br Dent J 1978 144 : 171 180.
26. Lee JJ, Hong WK, Hittleman WN, Mao L, Lotan R, Shin DM. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000 6 : 1702 1710.
27. Silverman S, Bhargava K, Smith LW, Malaowalla AM. Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer 1976 38 : 1790 1795.
28. Holmstrup P, Vedtofte P, Reibel J, Stoltze K. Long-term treatment outcome of oral premalignant lesions. Oral Oncol 2006 42 : 461 474.
29. Mithani SK, Mydlarz WK, Grumbine FL, Smith JM, Califano JA. Molecular genetics of premalignant oral lesions. Oral Dis 2006 13 : 126 133.
30. Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol 2005 86 : 347 363.
31. Kannan R, Bijur GN, Mallery SR, et al. Transforming growth factor-alpha over expression in proliferative verrucous leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996 82 : 69 74.
32. Beenken SW, Sellers MT, Huang P, et al. Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid. Head Neck 1999 21 : 566 573.
33. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor-alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993 53 : 3579 3584.
34. Srinivasan M, Jewell SD. Evaluation of TGF-α and EGFR expression in oral leukoplakia and oral submucous fibrosis by quantitative immunohistochemistry. Oral Oncol 2001 61 : 284 292. (Pubitemid 33135837)
35. Shah NG, Trivedi TI, Tankshali RA, et al. Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 2007 22 : 132 143.
36. Shin D, Ro J, Hong W, Hittelman W. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994 54 : 3153 3159. (Pubitemid 24208920)
37. Christensen M. The EGF receptor system in head and neck carcinomas and normal tissues. Immunohistochemical and quantitative studies. Dan Med Bull 1998 45 : 121 134.
38. Birgler W, Bier H, Ganzer U. The expression of epidermal growth factor receptors in oral mucosa of patients with oral cancer. Arch Otolaryngol 1989 246 : 121 125.
39. Fillip MI, Osborn M, Linehan J, Sanidas E, Brito MJ, Janowski J. Expression of transforming growth factor-alpha, epidermal growth factor receptor in precursor lesions to gastric carcinoma. Br J Cancer 1995 71 : 30 6.
40. Koppert LB, Wijhoven BPL, Dekken HV, Tilanus HW, Dinjens WNM. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005 92 : 169 190.
41. Kilpi A, Rich AM, Konttinen YT, Reade PC. Expression of c-erbB2 protein in keratinocytes of oral mucosal lichen planus and subsequent squamous cell carcinoma. Eur J Oral Sci 1996 104 : 278 284.
42. Werkmeister R, Brandt B, Joos U. Aberrations of erbB-2 oncogenes in non-dysplastic leukoplakias of the oral cavity. Br J Oral Maxillofac Surg 1999 37 : 477 480.
43. Warnakulasuriya KAAS, Johnson NW. Expression of p53 mutant nuclear phosphoprotein in oral carcinoma and potentially malignant oral lesions. J Oral Pathol Med 1992 21 : 404 408.
44. Chang SE, Bhatia P, Johnson NW. Ras mutations in United Kingdom examples of oral malignancies are infrequent. Int J Cancer 1991 48 : 409 412.
45. Saranath D, Bhoite LT, Mehta AR, Sanghavi V, Deo MG. Loss of allelic heterozygosity at the harvey ras locus in human oral carcinomas. J Cancer Res Clin Oncol 1991 117 : 484 488.
46. Suzui M, Yoshimi N, Tanka T, Mori H. Infrequent Ha-ras mutations and absence of Ki-ras, N-ras and p53 mutations in 4-nitroquinilone 1-oxide induced rat oral lesions. Mol Carcinogenesis 1995 14 : 294 298.
47. Yuan B, Heniford BW, Ackerman DM, et al. Harvey ras (H-ras) point mutations are induced by 4-nitroquinilone 1-oxide in murine oral squamous epithelia, while squamous cell carcinomas and loss of heterozygosity occur without additional exposure. Cancer Res 1994 54 : 5310 5317.
48. Garnis C, Coe BP, Ishkanian A, Zhang L, Rosin MP, Lam WL. Novel regions of amplification on 8q distinct from the MYC locus and frequently altered in oral dysplasia and cancer. Genes Chromosomes Cancer 2004 39 : 93 8.
49. Kang MK, Kim RH, Kim SJ, et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 2007 96 : 126 133.
50. Turatti E, da Costa Neves A, de Magalhães MH, de Sousa SO. Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci 2005 47 : 71 6.
51. Gstaiger M, Jordan R, Lim M, et al. Skp-2 is oncogenic and over expressed in human cancers. Proc Natl Acad Sci U S A 2001 98 : 5043 5048.
52. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995 47 : 545 560.
53. Bartkova J, Lukas J, Müller H, Strauss M, Gusterson B, Bartek J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res 1995 55 : 949 956.
54. Gimenez-Conti IB, Collet AM, Lanfranchi H, et al. p53, Rb, and cyclin D1 expression in human oral verrucous carcinomas. Cancer 1996 78 : 17 23.
55. Davidson BJ, Lydiatt WM, Abate MP, Schantz SP, Chaganti RSK. Cyclin D1 abnormalities and tobacco exposure in head and neck squamous cell carcinoma. Head Neck 1996 18 : 512 521.
56. Xu J, Gimenez-Conti IB, Cunningham JE, et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 1998 83 : 204 212.
57. Kotelnikov VM, Coon JS, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997 3 : 95 101.
58. Sawa H, Oshima AO, Ukita H, et al. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998 16 : 1701 1712.
59. Mihara M, Shintani S, Nakahara Y, et al. Over expression of CDK2 is a prognostic indicator of oral cancer progression. Jpn J Cancer Res 2001 92 : 352 360.
60. Oliver RJ, Macdonald DG. G1 cyclins in oral epithelial dysplasia. J Oral Pathol Med 2001 30 : 80 6.
61. Soni S, Kaur J, Kumar A, et al. Alterations of Rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005 68 : 314 325.
62. Izzo JG, Papadimitrakopoulou VA, Li XQ, et al. Dysregulated cyclin D1 expression early in head and neck tumorigenesis: in vivo evidence for an association with subsequent gene amplification. Oncogene 1998 17 : 2313 2322.
63. Rousseau A, Lim MS, Lin Z, Jordan RC. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol 2001 37 : 268 275.
64. Kovesi G, Szende B. Prognostic value of cyclin D1, p27 and p 63 in oral leukoplakia. J Oral Pathol Med 2006 35 : 274 277.
65. Papadimitrakopoulou V, Izzo JG, Liu DD, et al. Cyclin D1 overexpression and cancer development in laryngeal premalignancy patients. Cancer Prev Res 2009 2 : 14 21.
66. Uhlman DL, Adams G, Knapp D, Aeppli DM, Niehans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res 1996 56 : 2199 2205.
67. Juan G, Li X, Darzynkiewicz Z. Correlation between DNA replication and expression of cyclins A and B1 in individual MOLT-4 cells. Cancer Res 1997 57 : 803 807.
68. Oliver RJ, Macdonald DG. Comparison of BrdU and cyclin A as a marker of the S phase in oral precancerous lesions. J Oral Pathol Med 2000 29 : 426 431.
69. Jordan RCK, Bradley G, Slingerland J. Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998 152 : 585 590.
70. Warnakulsuriya KAAS, Tavassoli M, Johnson NW. Relationship of p53 over expression to other cell cycle regulatory proteins in oral squamous cell carcinoma. J Oral Pathol Med 1998 27 : 367 371.
71. Blons H, Laurent-Puig P. TP53 and head and neck neoplasms. Review. Hum Mutat 2003 21 : 252 257.
72. Boyle JO, Hakim J, Koch W, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993 53 : 4477 4480.
73. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996 56 : 2488 2492.
74. Lane DP, Lu X, Hupp T, Hall PA. The role of the p53 protein in the apoptotic response. Philos Trans R Soc Lond B Biol Sci 1994 345 : 277 280.
75. Slootweg PJ, Koole R, Hordijk GJ. The presence of p53 protein in relation to Ki67 as cellular proliferation marker in head and neck squamous cell carcinoma and adjacent dysplastic mucosa. Oral Oncol 1994 30 : 138 141.
76. Girod SC, Pfeiffer P, Ries J, Pape HD. Proliferative activity and loss of function of tumor suppressor genes as "biomarkers" in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Max Surg 1998 36 : 252 260.
77. Kushner J, Bradley G, Anderson C. Patterns of p53 and Ki67 protein expression in epithelial dysplasia from the floor of the mouth. J Pathol 1997 183 : 418 423.
78. Murti PR, Warnakulasuriya KA, Johnson NW, Bhonsle RB, Gupta PC, Daftary DK. P53 expression in oral pre cancer as a marker for malignant potential. J Oral Pathol Med 1998 27 : 191 196.
79. Shahnavaz SA, Regezi JA, Bradley G, Dube ID, Jordan RC. P53 gene mutations in sequential oral epithelial dysplasias and squamous cell carcinomas. J Pathol 2000 190 : 417 422.
80. Warnakulasuriya S. p53 and oral precancer. Oral Oncology VI 1999 6 : 93 6.
81. Cruz IB, Snijders PJF, Meijer CJ. P53 expression above the basal cell layer in oral mucosa is an early event of malignant transformation and has predictive value for developing oral squamous cell carcinoma. J Pathol 1998 184 : 360 368.
82. Shin DM, Kim J, Ro JY, et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994 54 : 321 326.
83. Abbas NF, Labib El-Sharkawy S, Abbas EA, Abdel Monem El-Shaer M. Immunohistochemical study of p53 and angiogenesis in benign and preneoplastic oral lesions and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 103 : 385 390.
84. Kashiwazaki H, Tonoki H, Tada M, et al. High frequency of p53 mutations in human oral epithelial dysplasia and primary squamous cell carcinoma detected by yeast functional assay. Oncogene 1997 15 : 2667 2674.
85. Lazarus P, Garewell HS, Sciubba J. A low incidence of p53 mutations in pre malignant lesions of the oral cavity from non tobacco users. Int J Cancer 1995 60 : 458 463.
86. Kusama K, Okutsu S, Takeda A, et al. p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma. J Pathol 1996 178 : 415 421.
87. Casson AG, Evans SC, Gillis A, Porter GA, et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinomas: results of a ten-year prospective study. J Thorac Cardiovasc Surg 2003 125 : 1121 1131.
88. Bennett WP, Holstein MC, Metcalf RA, et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992 52 : 6092 6097.
89. Sozzi G, Miozzo M, Donghi R, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992 52 : 6079 6082.
90. Field JK, Spandidos DA, Stell PM. Over expression of p53 gene in head and-neck cancer, linked with heavy smoking and drinking. Lancet 1992 339 : 502 503.
91. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992 89 : 7262 7266.
92. Cesarman E, Ingihirami G, Chardburn A, Knoeles DM. High levels of p53 protein expression do not correlate with p53 gene mutations in anaplastic large cell lymphoma. Am J Pathol 1993 143 : 845 856.
93. Hall PA, Meek D, Lane DP. Editorial. p53 - integrating the complexity. J Pathol 1996 180 : 1 5.
94. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cycln dependant kinases. Cell 1993 75 : 805.
95. El-Deiry WS, Tokino JW, Velculescu VE. WAF 1, a potential mediator of p53 tumor suppression. Cell 1993 75 : 817 825.
96. WAF1/CIP1 expression by p53 independent pathways. Oncogene 1996 12 : 1557 1564.
97. WAF1 immunoreactivity with the outcome of oral verrucous leukoplakia in Taiwan. J Oral Pathol Med 2000 29 : 56 62.
98. Erber R, Klein W, Andl T. Aberernt p21 protein accumulation in head and neck cancer. Int J Cancer 1997 74 : 383 389.
99. Venkatesan TK, Kuropkat C, Caldarelli DD, et al. Prognostic significance of p27 expression in carcinoma of the oral cavity and oropharynx. Laryngoscope 1999 109 : 1329 1333.
100. Jeannon JP, Soames JV, Aston V, Stafford SW, Wilson JA. Molecular markers in dysplasia of the larynx. Expression of cyclin dependant kinase inhibitors p21, p27and p53 tumor suppressor gene in predicting cancer risk. Clin Otolaryngol 2004 29 : 698 704.
101. Jordan RCK, Bradley G, Slingerland J. Reduced level of the cell cycle inhibitor p27 in epithelial dysplasia and carcinoma of the oral cavity. Am J Pathol 1998 142 : 585 590.
102. Katayose Y, Kim M, Rakkar ANS, Cowan KH, Seth P. Promoting apoptosis; a novel activity associated with the cyclin-dependant kinase inhibitor p27. Cancer Res 1997 57 : 5441 5445.
103. Wu X, Bayle JH, Oslon D, Levine AJ. The p53-MDM2 auto regulatory feedback loop. Genes Dev 1993 7 : 1126 1132.
104. Bueso-Ramos CE, Yang Y, De Leon E, Mccown P, Stass SA, Albitar M. The human MDM2 oncogene is over expressed in leukemias. Blood 1993 82 : 2613 2617.
105. Sheikh MS, Shao ZM, Hussain A, Fontana JA. The p53 binding protein is differentially expressed in human breast carcinoma. Cancer Res 1993 53 : 3226 3228.
106. Lim KP, Sharifa H, Lau SH, Teo SH, Cheong SC. Alterations of the p14ARF-p53-MDM2 pathway in oral squamous cell carcinoma. MDM2 overexpression is a common event. Oncol Rep 2005 14 : 963 968.
107. Agarwal S, Mathur M, Srivastava A, Ralhan R. MGM2/p53 co expression in oral pre malignant lesions; potential prognostic implications. Oral Oncol 1999 35 : 209 216.
108. Chen YK, Hsue SS, Lin LM. Expression of p63 protein and mRNA in oral epithelial dysplasia. J Oral Pathol Med 2005 34 : 232 239.
109. Hu H, Xia SH, Li AD. Elevated expression of p63 protein in human esophageal squamous cell carcinoma. Int J Cancer 2002 102 : 580 583.
110. Pelosi G, Pasni F, Oslen Stenholm C. The p63 immuno reactivity in lung cancer. Yet another player in the development of squamous cell carcinoma. J Pathol 2002 98 : 100 109.
111. Reis-Filho JS, Toio B, Abergaria A, Schmitt FC. P63 expression in normal skin and cutaneous carcinomas. J Cutan Pathol 2002 29 : 517 523.
112. Chen YK, Huse SS, Lin LM. Immunohistochemical demonstration of p63 in DMBA-induced hamster buccal pouch squamous cell carcinogenesis. Oral Dis 2003 9 : 235 240.
113. Chen YK, Huse SS, Lin LM. Immuno histochemical demonstration of p73 protein in the early stages of DMBA induced squamous cell carcinoma in hamster buccal pouch. Arch Oral Biol 2002 47 : 695 699.
114. Nylander K, Coates PJ, Hall PA. Characterization of the expression pattern of p63α and Np63α in benign and malignant oral epithelial lesions. Int J Cancer 2000 87 : 368 372.
115. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RCK, Regezi JA. Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004 98 : 698 704.
116. Papadimitrakopoulou V, Izzo J, Lippman SM, et al. Frequent inactivation of p16INK4α in oral premalignant lesions. Oncogene 1997 14 : 1799 1803.
117. Rocco JW, Sidranky D. p16 (MTS-CDKN2/INK4) in cancer progression. Exp Cell Res 2001 264 : 42 55.
118. Gologan O, Barnes EL, Hunt JL. Potential diagnostic use of p16INK4A, a new marker that correlates with dysplasia in oral squamoproliferative lesions. Am J Surg Pathol 2005 29 : 792 796.
119. Bradley KT, Budnick SD, Logani S. Immunohistochemical detection of p16INK4a in dysplastic lesions of the oral cavity. Mod Pathol 2006 19 : 1310 1316.
120. Esteller M, Cordon-Cardo C, Corn PG, et al. The p14arf silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 2001 61 : 2816 2821.
121. Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999 9 : 22 30.
122. ARF in patients with severe oral epithelial dysplasia. Cancer Res 2002 62 : 5295 5300.
123. Bates S, Phillips AC, Cark PA, et al. P14ARF links the tumor suppressors RB and p53. Nature (Lond) 1998 395 : 124 125.
124. Ralhan R, Chakravarti N, Kaur J, et al. Clinical significance of altered expression of retinoid receptors in oral precancerous and cancerous lesions: relationship with cell cycle regulators. Int J Cancer 2006 118 : 1077 1089.
125. Campisi J. Cancer, aging and cellular senescence. In Vivo 2000 14 : 183 188.
126. Kiyono T, Foster SA, Koop JI, et al. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature 1998 396 : 84 8.
127. Niwa S, Ueno S, Shirasu R. Alteration of pRb expression in the development of rat tongue carcinoma induced by 4-nitroquinoline 1-oxide. Oral Oncol 2001 37 : 579 585.
128. Femiano F, Scully C. DNA cytometry of oral leukoplakia and oral lichen planus. Med Oral Pathol Oral Cir Bucal 1 2005 10 (Suppl. 1 E9 14.
129. Sen S. Aneuploidy and cancer. Curr Opin Oncol 2000 12 : 82 8.
130. Abdel-Salam M, Mayall BH, Chew K, Silverman S. Which oral white lesions will become malignant? An image cytometric study. Oral Surg Oral Med Oral Pathol 1990 69 : 345 350.
131. Raimondi A, Cabrini R, Itoiz ME. Ploidy analysis of field cancerization and cancer development in the hamster cheek pouch carcinogenesis model. J Oral Pathol Med 2005 34 : 227 231.
132. Klanrit P, Sperandio M, Brown AL, et al. DNA ploidy in proliferative verrucous leukoplakia. Oral Oncol 2007 43 : 310 316.
133. Hirshberg A, Yarom N, Amariglio N, et al. Detection of non-diploid cells in premalignant and malignant oral lesions using combined morphological and FISH analysis-a new method for early detection of suspicious oral lesions. Cancer Lett 2007 253 : 282 290.
134. Torres-Rendon A, Stewart R, Craig CT, Wells M, Speight PM. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with high risk of malignant progression. Oral Oncol 2009 45 : 468 473.
135. Steinbeck RG. Atypical mitoses in lesions of the oral mucosa: a new interpretation of their impact upon tumorigenesis. Oral Oncol 1997 33 : 110 118.
136. Zhang L. Loss of heterozygosity: a potential tool in management of oral premalignant lesions? J Oral Pathol Med 2001 30 : 513 520.
137. Partridge M. A case control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000 60 : 3893 3898.
138. Rosin MP. Use of allelic loss to predict malignant risk of low-grade oral epithelial dysplasia. Clin Cancer Res 2000 6 : 357 362.
139. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosome 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996 2 : 682 685.
140. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aero digestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001 7 : 3127 3134.
141. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumors. Br J Cancer 1999 81 : 677 683.
142. Emilion G, Langdon JD, Speight P, Partridge M. Frequent gene deletions in potentially malignant oral lesions. Br J Cancer 1996 73 : 809 13.
143. Partridge M, Emilion G, Falworth M, et al. Patient specific databases for oral cancer. Int J Cancer 1999 84 : 284 292.
144. Bremmer JF, Braakhuis BJ, Brink A, et al. Comparative evaluation of genetic assays to identify oral pre-cancerous fields. J Oral Pathol Med 2008 37 : 599 606.
145. Tanda N, Mori S, Saito K, Ikawa K, Sakamoto S. Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies. J Oral Pathol Med 2000 29 : 385 393.
146. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997 88 : 323 331.
147. Haupt Y, Barak Y, Oren M. Cell type-specific inhibition of p53-mediated apoptosis by MDM2. EMBO J 1996 15 : 1596 1606.
148. Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol 1998 13 : 521 530.
149. Jordan RCK, Catzavelos GC, Barrett AW, Speight PM. Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity. Oral Oncol 1996 32 : 394 400.
150. Singh BB, Chandler FW Jr., Whitaker SB, Forbes-Nelson AE. Immunohistochemical evaluation of bcl-2 oncoprotein in oral dysplasia and carcinoma. Oral Surg Oral Med Oral Pathol Oral Radio Endod 1998 85 : 692 698.
151. Ravi D, Ramadas K, Mathew BS, Nalinakumari KR, Nair MK, Pillai MR. De novo programmed cell death in oral cancer. Histopathol 1999 34 : 241 249.
152. Schoelch ML, Le QT, Silverman S Jr., et al. Apoptosis-associated proteins and the development of oral squamous cell carcinoma. Oral Oncol 1999 35 : 77 85.
153. McAlinden RL, Maxwell P, Napier S, et al. Bcl-2 expression in sequential biopsies of potentially malignant oral mucosal lesions assessed by immunocytochemistry. Oral Dis 2000 6 : 318 326.
154. Taniguchi Y, Nagao T, Maeda H, Kameyama Y, Warnakulasuriya KAAS. Epithelial cell proliferation in oral lichen planus. Cell Prolif 2002 35 : 103 109.
155. Jain A, Maheshwari V, Alam K, Mehdi G, Sharma SC. Apoptosis in premalignant and malignant squamous cell lesions of the oral cavity: a light microscopic study. Indian J Pathol Microbiol 2009 52 : 164 166.
156. Loro LL, Vintermyr OK, Liavaag PG, Jonsson R, Johannessen AC. Oral squamous cell carcinoma is associated with decreased bcl-2/bax expression ratio and increased apoptosis. Hum Pathol 1999 30 : 1097 1105.
157. Izawa H, Yonemitsu N, Shin T, Sugihara H. Histopathological analysis of apoptosis, and expression of p53, bcl-2, bax, and Ki-67 in laryngeal squamous cell carcinomas and dysplasia. Auris Nasus Larynx 1999 26 : 317 330.
158. Syafriadi M, Cheng J, Jen KY, Ida-Yonemochi H, Suzuki M, Saku T. Two phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apoptosis of prickle cells. J Oral Pathol Med 2005 34 : 140 149.
159. Okazaki Y, Tanaka Y, Tonogi M, Yamane G. Investigations of environmental factors for diagnosing malignant potential in oral epithelial dysplasia. Oral Oncol 2002 38 : 562 573.
160. Kohno Y, Patel V, Kim Y, et al. Apoptosis, proliferation and p21doc)1 profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol 2002 38 : 274 280.
161. Birchall MA, Winterford CM, Allan DJ, Harmon BV. Apoptosis in normal epithelium, premalignant and malignant lesions of the oropharynx and oral cavity: a preliminary study. Oral Oncol 1995 31 : 380 383.
162. Cheng B, Rhodus NL, Williams B, Griffin RJ. Detection of apoptotic cells in whole saliva of patients with oral pre malignant and malignant lesions: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004 97 : 465 470.
163. Lo Muzio L, Pannone G, Leonardi R, et al. Survivin, a potential early predictor of tumor progression in the oral mucosa. J Dent Res 2003 82 : 923 928.
164. Lin CY, Hung HC, Kuo RC, Chiang CP, Kuo MY. Survivin expression predicts poorer prognosis in patients with areca quid chewing related oral squamous cell carcinoma in Taiwan. Oral Oncol 2005 41 : 645 654.
165. Shibata M, Kodani I, Osaki M, et al. Cyclo-oxygenase 1 and 2 expression in oral mucosa, dysplasia and squamous cell carcinomas and their pathological significance. Oral Oncol 2005 41 : 304 312.
166. Sun XJ, Ma J, Zhang H, Wang XK, Li JH. The expression of cyclooxygenase-2 (Cox-2), VEGF in oral squamous cell carcinoma and precancerous lesions and their significance. Shanghai Kou Qiang Yi Xue 2005 14 : 173 176.
167. Zhang S, Du Y, Tao J, Wu Y, Chen N. Expression of cytosolic phospholipase A2 and cyclooxygenase 2 and their significance in human oral mucosae, dysplasias and squamous cell carcinomas. ORL 2008 70 : 242 248.
168. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev 2002 82 : 331 371.
169. Pedrero JMG, Fernandez MP, Morgan RO, et al. Annexin 1 down regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 2004 164 : 73 9.
170. Paweletz CP, Ornstein DK, Roth MJ, et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000 60 : 6293 6297.
171. Soukka T, Pohjola J, Inki P, Happonen RP. Reduction of syndecan-1 expression is associated with dysplastic oral epithelium. J Oral Pathol Med 2000 29 : 308 313.
172. Jackson LL, Wade Z, Hessler RB, Abdelsayed R, Rogers JB, Gourin CG. Quantitative analysis of syndecan-1 expression in dysplasia and squamous cell carcinoma of the oral cavity. Laryngoscope 2007 117 : 868 871.
173. Tsukita Sa, Yonemura S, Tsukita Sh. ERM family: (ezrin/radixin/moesin) from cytoskeleton to signal transduction. Curr Opin Cell Biol 1997 9 : 70 5.
174. Ichikawa T, Masumoto J, Kaneko M, Saida T, Sagara J, Taniguchi S. Expression of meosin and its associated CD44 in epithelial skin tumors. J Cutan Pathol 1998 25 : 237 243.
175. Kobayashi H, Sagara J, Musumoto J, Kurita H, Kurashina K, Taniguchi S. Shifts in cellular localization in moesin in normal oral epithelium, oral epithelial dysplasia, verrucous carcinoma and oral squamous cell carcinoma. J Oral Pathol Med 2003 32 : 344 349.
176. Giannelli G, Milillo L, Marinosci F, Lo Muzio L, Serpico R, Antonaci S. Altered expression of integrins and basement membrane proteins in malignant and pre-malignant lesions of oral mucosa. J Biol Regul Homeost Agents 2001 15 : 375 380.
177. Meyer JR, Silverman S Jr., Daniels TE, Kramer RH, Greenspan JS. Distribution of fibronectin and laminin in oral leukoplakia and carcinoma. J Oral Pathol 1985 14 : 247 255.
178. Kannan S, Balaram P, Chandran GJ, et al. Alterations in expression of basement membrane proteins during tumor progression in oral mucosa. Histopathology 1994 24 : 531 537. (Pubitemid 24199255)
179. Tosios KI, Kapranos N, Papanicolaou SI. Loss of basement membrane components laminin and type IV collagen parallels the progression of oral epithelial neoplasia. Histopathology 1998 33 : 261 268.
180. Williams HK, Sanders DS, Jankowski JA, Landini G, Brown AM. Expression of cadherins and catenins in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med 1998 27 : 308 317.
181. Lo Muzio L, Lo Russo L, Falaschini S, et al. β- and γ-Catenin expression in oral dysplasia. Oral Oncol 2009 45 : 501 504.
182. Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, et al. Adhesion molecule CD44 as a prognostic factor in tongue cancer. Anticancer Res 2003 23 : 5197 5202.
183. Begum S, Zhang Y, Shintani T, Toratani S, Sato JD, Okamoto T. Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1(HBp17/FGFBP-1) as an oncogenic factor in head and neck tumorigenesis. Oncol Rep 2007 17 : 591 596.
184. Brennan PA, Umar T, Wilson AW, Mellor TK. Expression of type 2 nitric oxide synthase and vascular endothelial growth factor in oral dysplasia. J Oral Maxillofac Surg 2002 60 : 1455 1460.
185. Stepnik M. Roles of nitric oxide in carcinogenesis. Protumorigenic effects. Int J Occup Med Environ Health 2002 15 : 219 227.
186. Thomsen LL, Miles DW. Role of nitric oxide in tumor progression: lessons from human tumors. Cancer Metastasis Rev 1998 17 : 107 118.
187. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998 90 : 587 596.
188. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993 362 : 841 844.
189. Chen Y, Kayano T, Takagi M. Dysregulated expression of bcl-2 and bax in oral carcinomas: evidence of post-transcriptional control. J Oral Pathol Med 2000 29 : 63 9.
190. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996 86 : 353 364.
191. Fujita H, Nagata M, Hoshina H, et al. Clinical significance and usefulness of quantification of telomerase activity in oral malignant and nonmalignant lesions. Int J Oral Maxillofac Surg 2004 33 : 693 699.
192. Mutirangura A, Supiyaphun P, Trirekapan S, et al. Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Res 1996 56 : 3530 3533.
193. Kannan S, Tahara H, Yokozaki H, et al. Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiol Biomarkers Prev 1997 6 : 413 420.
194. Chen HH, Yu CH, Wang JT, et al. Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan. Oral Oncol 2007 43 : 122 129.
195. Pannone G, De Maria S, Zamparese R, et al. Prognostic value of human telomerase reverse transcriptase gene expression in oral carcinogenesis. Intl J Oncol 2007 30 : 1349 1357.
196. Ray JG, Chattopadhyay A, Caplan DJ. Usefulness of AgNOR counts in diagnosing epithelial dysplasia. J Oral Pathol Med 2003 32 : 71 6.
197. Warankulasuriya KAAS, Johnson NW. Nucleolar organiser region (NOR) distribution as a diagnostic marker in oral keratosis, dysplasia and squamous cell carcinoma. J Oral Pathol Med 1993 22 : 77 81.
198. Warnakulasuriya KAAS, Macdonald DG. Epithelial cell kinetics in oral leukoplakia. J Oral Pathol Med 1995 24 : 165 169.
199. Gonzalez-Moles MA, Rodreguez-Archilla A. Supra basal expression of Ki67 antigen as a marker for the presence and severity of oral epithelial dysplasia. Head Neck 2000 22 : 658 661.
200. Vered M, Allon I, Dayan D. Maspin, p53, p63 and Ki67 in epithelial lesions of the tongue: from hyperplasia through dysplasia to carcinoma. J Oral Pathol Med 2009 38 : 314 320.
201. Torres-Rendon A, Roy S, Craig GT, Speight PM. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasia and their corresponding squamous cell carcinomas. Br J Cancer 2009 100 : 1128 1134.
202. Montebugnoli L, Felicetti L, Gissi DB, et al. Predictive role of p53 as a single marker or associated to Ki67 antigen in oral carcinogenesis. The Open Dent J 2009 2 : 24 9.
203. Reibel J, Clausen H, Dabelsteen E. Staining patterns of human pre malignant oral epithelium and squamous cell carcinomas by monoclonal anti keratin antibodies. Acta Pathol Microbiol Immunol Scand 1985 93 : 323 330.
204. Bloor BK, Ouhayoun JP, Morgan PR. Gene expression of differentiation specific keratins in oral epithelial dysplasia and squamous cell carcinoma. Oral Oncol 2001 37 : 251 261.
205. Nie M, Zhong L, Zeng G, Li B. The changes of cytokeratin 19 during oral carcinogenesis. Zhonghua Kou Qiang Yi Xue Za Zhi 2002 37 : 187 190.
206. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: The International Agency for research on Cancer Multicenter study. J Nat Cancer Int 2003 95 : 1772 1783.
207. Miller CS, Johnstone BM. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001 91 : 622 635.
208. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. The New Eng J Med 2007 356 : 1944 1956.
209. Elamin F, Steingrimsdottir H, Warnakulasuriya S, Johnson NW, Tavassoli M. Prevalence of human papillomavirus infection in premalignant and malignant lesions of the oral cavity in the UK subjects: a novel method of detection. Oral Oncol 1998 34 : 191 197.
210. Sugerman PB, Shillitoe EJ. The high risk human papillomavirus and oral cancer: evidence for and against a causal relationship. Oral Dis 1997 3 : 130 147.
211. Mork J, Lie AK, Hallmans G, et al. Human papillomavirus infection as a risk factor for squamous cell carcinoma of the head and neck. N Eng J Med 2001 344 : 1125 1131. (Pubitemid 32285233)
212. Luo CW, Roan CH, Liu CJ. Human papillomavirus in oral squamous cell carcinoma and precancerous lesions detected by PCR-based gene-chip array. Int J Oral Maxillofac Surg 2007 36 : 153 158.
213. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review. Cancer Epedinol, Biomarkers Prev 2005 14 : 467 475.
214. Palefsky JM, Silverman S Jr., Abdel-Salaam M, Daniels TE, Greenspan JS. Association between proliferative verrucous leukoplakia and infection with human papillomavirus type 16. J Oral Pathol Med 1995 24 : 193 197.
215. Campisi G, Panzarella V, Giuliani M, et al. Human papillomavirus: its identity and controversial role in oral oncogenesis, premalignant and malignant lesions (review). Int J Oncol 2007 30 : 813 823.
216. Bagan JV, Jimenez Y, Murillo J, et al. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg 2007 65 : 46 54.